Oppenheimer Downgrades Crinetics Pharmaceuticals to Perform

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

Oppenheimer analyst Leland Gershell downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outperform to Perform.

Comments

No comments yet. Be the first!